Meet Jordan
Dr. Shin is a medical professional with extensive experience in clinical practice and clinical development initiatives particularly in the gene therapy space. He was Senior Vice President (VP) of Clinical Development and Translational Science, Cardiology at LEXEO Therapeutics where he led the AAV gene therapies aimed at treating cardiomyopathy caused by Friedreich Ataxia and PKP2-mediated arrhythmogenic cardiomyopathy from IND acceptance to first patient dosing.Before joining LEXEO, Dr. Shin held the position of Senior VP of Clinical Development and Translational Science at Renovacor, which was later acquired by Rocket Pharma. During his time at Renovacor, he was instrumental in planning translational research and developing the clinical strategy for its Bag3 gene therapy, serving as the strategic lead for the project team.
At Lung Biotechnology, a subsidiary of United Therapeutics, PBC, Dr. Shin was VP of Medical Development. His leadership was crucial in the clinical design, oversight and execution of the company’s small molecule programs, devices, cardiac and renal xenotransplantation and cell and gene therapies.Dr. Shin had a distinguished academic career as a physician-scientist at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. He specialized in treating patients with advanced heart failure and heart transplant. He holds an MD and PhD from the University of Alabama and a bachelor's from Harvard.
As HAYA CMO, Jordan will provide strategic direction and leadership to the company's clinical activities. He will focus on demonstrating the clinical relevance and translatability of HAYA’s regulatory genome targeting therapeutic approach and its impact on human disease.
